

Amendments to the Claims:

Please cancel claims 1-38 without prejudice. Please add new claims 39-55 as follows. This listing of claims will replace all prior versions and listings of claims in this application:

Listing of Claims:

1-38. (Cancelled)

39. (New) The antibody or antigen-binding fragment thereof that binds to a type III epitope of pleiotrophin (PTN) and neutralizes at least one biological activity of PTN.

40. (New) The antibody or antigen-binding fragment thereof according to claim 39 comprising:

(a) an antibody or antigen-binding fragment thereof that binds to substantially the same epitope as a monoclonal antibody or antigen-binding fragment thereof produced by a hybridoma cell line selected from the group consisting of 3B10, 4B2, 10, 17, 24, 25, 26, 27, 31, 41, 50, 60, 87, 3-4A, and 3-11FA;

(b) a monoclonal antibody or antigen-binding fragment thereof produced by a hybridoma cell line selected from the group consisting of 3B10, 4B2, 10, 17, 24, 25, 26, 27, 31, 41, 50, 60, 87, 3-4A, and 3-11F; or

(c) an antibody that competitively inhibits binding of a PTN polypeptide to an antibody comprising a sequence selected from SEQ ID NOs: 3, 5, 6, 7, 8, 10, 11, and 12.

41. (New) The antibody or antigen-binding fragment thereof according to claim 39, wherein said biological activity is selected from the group consisting of: receptor binding activities, signaling transduction activities, or cellular responses induced by PTN.

42. (New) The antibody or antigen-binding fragment thereof according to claim 39, wherein said antibody inhibits cancer cell growth.

43. (New) The antibody or antigen-binding fragment thereof according to claim 39, wherein said antibody inhibits cancer cell proliferation.
44. (New) The antibody or antigen-binding fragment thereof according to claim 39, wherein said antibody inhibits metastasis of cancer cells.
45. (New) The antibody or antigen-binding fragment thereof according to claim 39, wherein said antibody inhibits angiogenesis induced by cancer cells.
46. (New) The antibody or antigen-binding fragment thereof according to claim 39, wherein said antibody comprises an amino acid sequence with at least about 90% sequence identity with a sequence selected from SEQ ID NOs:3, 5, 6, 7, 8, 10, 11, and 12.
47. (New) The antibody or antigen-binding fragment thereof according to the claim 39, wherein said antibody comprises an amino acid sequence selected from SEQ ID NOs: 3 and 8.
48. (New) The antibody or antigen-binding fragment thereof according to claim 39, wherein said antibody is a monoclonal antibody.
49. (New) The antibody or antigen-binding fragment thereof according to claim 39, wherein said antibody is selected from the group consisting of a polyclonal antibody, chimeric antibody, humanized antibody, or a fully human antibody.
50. (New) The antibody or antigen-binding fragment thereof according to claim 39, wherein said antigen-binding fragment is selected from the group consisting of Fab fragment, (Fab')₂ Fragment, or a Fv fragment.
51. (New) The antibody or antigen-binding fragment thereof of claim 39, wherein the antibody is conjugated to a cytotoxic agent.
52. (New) A polypeptide comprising an amino acid sequence selected from SEQ ID NOs: 3, 5, 6, 7, 8, 10, 11, and 12.

53. (New) The antibody or antigen-binding fragment thereof according to claim 39, wherein said antibody binds to a PTN epitope at a binding affinity of at least 10^6M^{-1} .

54. (New) A pharmaceutical composition comprising the antibody according to claim 39 and a pharmaceutical carrier.

55. (New) An isolated monoclonal antibody produced by the method comprising:

- 1) selecting a host animal;
- 2) immunizing said host animal with a fusion protein comprising said protein connected with a T-cell epitope;
- 3) isolating a lymphoid cell from said host animal;
- 4) fusing said lymphoid cell to a myeloma cell, so that a hybrid cell is created;
- 5) cultivating said hybrid cell; and
- 6) isolating a monoclonal antibody against said protein.